As of 4:15pm ET
| -0.06 / -1.14%|
The 7 analysts offering 12-month price forecasts for BioCryst Pharmaceuticals Inc have a median target of 8.00, with a high estimate of 12.00 and a low estimate of 4.00. The median estimate represents a +53.55% increase from the last price of 5.21.
The current consensus among 8 polled investment analysts is to Buy stock in BioCryst Pharmaceuticals Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.